Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Moderna, Inc. — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $25.47, while Moderna, Inc. trades at $62.97 (market cap $27.09B). The key difference: Moderna, Inc. is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMLC | MRNA | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $26.59 | $81.80 |
52-Week Low | $24.83 | $22.36 |
Market Cap | — | $27.09B |
Enterprise Value | — | $23.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $25.47 with minimal daily movement (-0.06%). Technical indicators show a bullish trend with moving averages supporting upward momentum, though oscillators remain neutral. The ETF maintains consistent dividend payments of $0.14 per share quarterly, providing income stability. Recent news highlights growing institutional interest in emerging market debt as investors seek yield above Treasury bonds.
The outlook remains positive given the 6.1% yield advantage over Treasuries, though currency risk and capital erosion concerns persist. Short interest has surged 73% recently, indicating some skepticism about sustainability. Federal Reserve policy decisions will be crucial for EM debt performance through 2026.
Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.
Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
